Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma.

Joseph A ImpellizeriAlessandra GavazzaEliana GreissworthAnna CrispoMaurizio MontellaGennaro CilibertoGeorge LubasLuigi Aurisicchio

Published in: Journal of translational medicine (2018)

Tel-eVax in combination with CHOP is safe and immunogenic in lymphoma canine patients. These data confirm the therapeutic efficacy of dTERT vaccine and hold promise for the treatment of dogs affected by other cancer types. More importantly, our findings may translate to human clinical trials and represent new strategies for cancer treatment.

Keyphrases

diffuse large b cell lymphoma
clinical trial
end stage renal disease
ejection fraction
chronic kidney disease
big data
peritoneal dialysis
squamous cell carcinoma
young adults
genome wide
copy number
combination therapy
lymph node metastasis
induced pluripotent stem cells